Abstract
Intravesical bacillus Calmette-Guérin (BCG) is widely used for the treatment of transitional cell carcinoma of the bladder. Although it is usually well tolerated, sepsis can occur, which has resulted in at least eight deaths [3]. The survival of Connaught BCG-infected mice treated with single and combination antibiotic and steroid therapy was evaluated. Triple-drug therapy with isoniazid, rifampin, and prednisolone resulted in 53% survival compared with 25% survival in the control group (P=0.0209). A survival of only 10.5% was observed with treatment using prednisolone alone. This survival was worse than that of the control group (25%), and approached statistical significance (P`0.0669). Our data suggest that BCG sepsis probably has components of both a hypersensitivity reaction and bacterial sepsis; they support the current use of combination antibiotic and steroid therapy for treatment of BCG sepsis in humans, but argue against treatment with steroids alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeHaven JI, Traynellis C, Riggs DR, Ting E, Lamm DL (1992) Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity. J Urol 147:738
Hunt JS, Silverstein MJ, Sparks FC, Haskell EM, Pilch YH, Morton DL (1973) Granulomatous hepatitis: a complication of BCG immunotherapy. Lancet II:820
Lamm DL, Steg A, Baccon-Gibod L, Morales A, Hanna MG, Pagano F, Alfthan O, Brosman S, Fisher HAF, Jakso G, Chisholm GD, Meijden APM van der, Debruyne FMJ (1989) Complications of bacillus Calmette-Guérin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. In: Debruyne FMJ, Denis L, Meijden APH van der (eds) EORTC genitourinary group monograph 6: BCG in superficial bladder cancer. Alan R. Liss, New York, p 335
Lamm DL, Meijden APM van der, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FMJ (1992) Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147:596
McKahn CF, Hendrickson CG, Spitler LE, Gunnarson A, Banerjee D, Nelson SR (1975) Immunotherapy of melanoma with BCG: two fatalities following intralesional injection. Cancer 35: 514
Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT (1990) Fatal sepsis following intravesical bacillus Calmette-Guérin administration for bladder cancer. J Urol 144:1328
Steg A, Leleu C, Debri B, Baccon-Gibod L, Sicard D (1989) Systemic bacillus Calmette-Guérin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. In: Debruyne FMJ, Denis L, Meijden APH van der (eds) EORTC genitourinary group monograph 6: BCG in superficial bladder cancer. Alan R. Liss, New York, p 325
Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL (1988) Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer. J Urol 139:94
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koukol, S.C., DeHaven, J.I., Riggs, D.R. et al. Drug therapy of bacillus Calmette-Guérin sepsis. Urol. Res. 22, 373–376 (1995). https://doi.org/10.1007/BF00296878
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00296878